Realize the benefits of objective monitoring in Huntington’s disease

Objective, sensitive and reliable markers of change in communication add value to clinical trials in Huntington’s disease. The dominant inheritance of Huntington’s disease means there is an opportunity for therapies to act before symptoms manifest. For trials to be effective in this space we need markers of disease that are sensitive to disease in the premanifest stage. Redenlab scientists have developed field leading methods and data for detecting subtle changes in performance during the premanifest stage of Huntingon’s disease, highlighting the sensitivity of speech to pathology in premanifest Huntington’s disease. Digital measures of speech and language offer great promise for trialists motivated by using cutting edge tools linked to meaningful outcomes.

Monitor Huntington’s disease early and efficiently

Huntington’s disease usually manifests in middle age, but carriers of the Huntingtin gene mutation can present with subtle deficits years before diagnosis. Redenlab’s data capture tools have proven sensitive to symptom change in the prodomal stages of Huntington’s disease, making it a promising tool for early disease monitoring. Read more about our work in the links below or contact us to learn more.

Latest news and updates

  • Posted on 17 October, 2021

    Redenlab’s latest iOS application provides state of the art audio capture, storage and analysis of speech and language data for monitoring brain health.

    • Posted on 27 September, 2021

      Dr Amir Lahav hired as Chief of Digital Health and Strategy. He is a clinical neuroscientist and a leading innovator in digital health with a special focus on developing and validating novel biomarkers and AI-driven technology for remote monitoring of patients with neurodegenerative diseases.